Hairy Cell Leukaemia of T‐cell Origin

Hernandez, Delmis E; Cruz, Conrad Russell Y.; Carnot, J; Dorticós, E; Espinosa, E.

doi:10.1111/j.1365-2141.1978.tb05822.x

Cited by 28 publications

(10 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…There have now been reports of four cases of hairy-cell leukaemia (HCL) in which the hairy cells (HCs) formed spontaneous rosettes with sheep erythrocytes (E rosettes) (Advani et al, 1976;Cawley ef al, 1978;Saxon et al, 1978;Hernandez et al, 1978). One of these cases also had B-cell features (Cawley et al, 1978), and we now describe another case with the same combined Band T-cell phenotype.…”

Section: T-cell Features In Hairy-cell Leukaemiamentioning

confidence: 69%

T‐cell Features in Hairy‐cell Leukaemia

et al. 1979

View full text Add to dashboard Cite

Section: T-cell Features In Hairy-cell Leukaemiamentioning

confidence: 69%

T‐cell Features in Hairy‐cell Leukaemia

et al. 1979

View full text Add to dashboard Cite

“…The controversy arises because hairy cells not only have certain B-cell characteristics, they also show some of the functional and phagocytic properties of the monocyte/histiocyte, and, rarely, display features of T-cells. However, the majority of evidence to date suggests that although rare T-cell variants have been described [2,3], most hairy cells arc committed to the B-cell lymphocytic line.…”

Section: The Hairy Cellmentioning

confidence: 99%

Hairy cell leukemia: clinical features and therapeutic advances

Lembersky

Golomb

1987

Cancer Metast Rev

View full text Add to dashboard Cite

Hairy cell leukemia (HCL) is a rare chronic lymphoproliferative disorder which has been extensively studied over the past decade. Much has been learned regarding the diagnosis, natural history, biology, and treatment of this unique neoplasm. The disease most commonly affects middle aged men and characteristic clinical features include splenomegaly, cytopenias, and usually the presence in the peripheral blood of distinctive 'hairy cells' with irregular cytoplasmic projections. Diagnosis can usually be confirmed by bone marrow biopsy. Although the natural history can be extremely variable among patients, complications are usually referable to the cytopenias, with anemia and infection being most frequent. In addition to pyogenic infections, patients are susceptible to unusual organisms including atypical mycobacterium, legionella, and fungi. The requirement of red blood cell transfusion, severe granulocytopenia or thrombocytopenia, frequent infections, or painful splenomegaly are all indications for treatment. Splenectomy is the standard initial treatment of choice. However, in the past few years there have been exciting major advances in the therapeutic modalities for HCL. Recombinant alpha-interferon is highly effective, with beneficial responses occurring in close to 90% of patients. The Food and Drug Administration has recently approved the use of interferon for HCL. This represents the first time a biological response modifier has been approved for the treatment of human disease. In addition, preliminary results with the adenosine deaminase inhibitor, 2'deoxycoformycin (dcf), have been encouraging. Further clinical trials are required in order to determine the optimal sequential treatment strategy for HCL. The exact mechanisms of action of both interferon and dcf in HCL remain to be elucidated. A better understanding of the unusual features of the hairy cell and the underlying biological effect of these two agents in HCL may have important applications in other hematologic and non-hematologic malignancies.

show abstract

“…Some have, however, reported an unusual phenotype seen neither in normal nor in other types of neoplastic B cells. In some instances the hairy cells were shown to express a T-cell antigen in addition to B-cell antigens (1,6,(9)(10)(11) and in others also a monocyte antigen (5,12,13). Another item, which has been a matter of some controversy, is the stage of maturation of HCL in relation to normal B-cell differentiation and to other chronic B-cell leukemias (3,14).…”

mentioning

confidence: 99%

Immunophenotype of hairy‐cell leukemia

Hassan

Hagberg

Sundström

1990

European J of Haematology

View full text Add to dashboard Cite

15 cases of HCL were studied with a panel of monoclonal antibodies against different leukocyte antigens. A B‐cell phenotype different from that of B‐CLL was observed (CD10‐, CD19+, CD20+, CD21‐, CD22+, CD37+, CD38‐, FMC7+, LN1+, PCA‐1+, BLy7+and CD5‐). As expected, CD11c and CD25 were positive and, in addition, a My7 and My9 positivity in varying degree was noted. 3 weeks of in vitro incubation did not significantly alter the phenotype. We conclude that HCL exhibits a unique phenotype among chronic B‐cell leukemias, which is closer to the plasma cell stage of differentiation than that of B‐CLL. The BLy7 monoclonal antibody seems to be a promising marker for HCL.

show abstract

Hairy Cell Leukaemia of T‐cell Origin

Cited by 28 publications

References 6 publications

T‐cell Features in Hairy‐cell Leukaemia

T‐cell Features in Hairy‐cell Leukaemia

Hairy cell leukemia: clinical features and therapeutic advances

Immunophenotype of hairy‐cell leukemia

Contact Info

Product

Resources

About